Sign in

    Jasmine

    Research Analyst at UBS

    Jasmine Hunet is a Senior Managing Director specializing in European Private Capital Advisory, with a focus on the secondary market for private equity and infrastructure. During her 13 years at UBS, she advised on high-profile strategic transactions including fund recapitalizations and large LP portfolio sales, working with major private equity and infrastructure firms across Europe. Known for leading some of the largest and most complex deals in the region, Hunet consistently delivered exceptional outcomes for clients, bolstered by deep expertise in both GP and LP advisory. She holds a Master in Management and Finance with dean’s honors from ESCP Europe, and is fluent in English, French, and conversant in Spanish.

    Jasmine's questions to Apellis Pharmaceuticals (APLS) leadership

    Jasmine's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Jasmine, on behalf of Eliana Merle at UBS, asked about the potential impact of a competitor's donation to co-pay foundations on Apellis's free drug usage and inquired about the latest compliance and adherence rates for Cyfovri.

    Answer

    CEO Dr. Cedric Francois reiterated that Apellis is independent of foundation management. CMO Dr. Caroline Baumal reported that real-world data from large physician groups shows Cyfovri compliance is around 80%, driven by motivated patients seeking to treat their persistent vision loss.

    Ask Fintool Equity Research AI

    Jasmine's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Jasmine, on behalf of Eliana Merle at UBS, asked about the potential impact of a competitor's donation to co-pay foundations on Apellis's free drug usage and inquired about the latest compliance and adherence rates for Cyfovri.

    Answer

    CEO Dr. Cedric Francois reiterated that foundation funding is independent of Apellis. CMO Dr. Caroline Baumal stated that real-world data from large physician groups indicates Cyfovri compliance is around 80%, driven by motivated patients seeking to treat their persistent vision loss.

    Ask Fintool Equity Research AI